Life Sciences
Vision fighter: Durham gene therapy startup lands $24.5M with clinical trial underway
Atsena Therapeutics – a clinical-stage gene therapy company that’s fighting to reverse and prevent blindness and recently launched a clinical trial…
DURHAM – Atsena Therapeutics – a clinical-stage gene therapy company that’s fighting to reverse and prevent blindness and recently launched a clinical trial for a possible treatment, has landed $24.5 million from investors to carry on the battle.
The funding came from 10 investors, according to an SEC filing.
Atsena wants to raise $30 million.
The company raised some $25 million in 2020.
Atsena recently announced that the first patient has been enrolled in a Phase I-II clinical trial for a treatment of a “subretinal injection” that it says can “achieve therapeutic levels of gene expression in photoreceptors of the central retina while avoiding the surgical risks of foveal detachment.”
The treatment is for X-linked retinoschisis, or XLRS. It is a “condition characterized by impaired vision that begins in childhood and occurs almost exclusively in males,” according to MedlinePlus.gov.
More Atsena coverage
Triangle’s gene therapy hub has another rising star: Atsena, targeting blindness
The post Vision fighter: Durham gene therapy startup lands $24.5M with clinical trial underway first appeared on WRAL TechWire.
Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner
The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….